All In Biotech

Drug Trial Radar · NCT05221658

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 ( Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) Combination Therapy or Monotherapy in Patients With Locally Advanced, Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Last checked: Nov 19, 2026Latest source record: Aug 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 25, 2022

Primary completion

Jun 30, 2024

Study completion Aug 30, 2025

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Feb 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted in patients with Locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) or esophageal adenosquamous carcinoma. This study includes three arms: A, B1, and B2. Arm A will receive HLX07 combination therapy with HLX10 and Chemotherapy (Cisplatin+5-FU) as first line treatment. Arm B (Patients with EGFR expression H score ≥ 200) and Arm C (Patients with EGFR expression H score \< 200) will receive HLX07 monotherapy as third-line or above treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).

Conditions

  • ESCC or Esophageal Adenosquamous Carcinoma

Interventions

  • HLX07+HLX10+ Cisplatin+5-FUDrug

    HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2

  • HLX07Drug

    HLX07 1000mg iv Q2w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: up to 2 years
  2. PFSTime frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academic of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Cancer Hospital Chinese Academic of Medical Sciences, Shenzhen Center

    Shenzhen, Guangdong, China · Not yet recruiting

  • Anyang Cancer Hospital

    Anyang, Hebei, China · Not yet recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Not yet recruiting

  • Henan Cancer Hospital & Affiliated Cancer Hospital of Zhengzhou University

    Zhenzhou, Henan, China · Not yet recruiting

  • Hunan Cancer Hospitla

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangsu People Hospital & The First Affiliated with Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Xuzhou Center Hospital

    Xuzhou, Jiangsu, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center

    Kunming, Yunnan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.